Long term beta-1 adrenergic blockade restores adrenomedullary activity in primary hypertension by Jacobs, M.C.G.S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/24316
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Journal af Cardiovascular Pharmacology™
30:338-342 © 1997 Lippincott-Raven Publishers, Philadelphia
Long-Term ßr  Adrenergic Blockade Restores Adrenomedullary 
Activity in Primary Hypertension
*Marie-Cécile Jacobs, ^Jacques W. M. Lenders, :l|Paul Smits, ^Jacques J. Willemsen,
*C. Tack, and Theo Thien
N
*Department o f  Medicine, Division o f  General Internai Medicine, ^Department o f  Pharmacology, 
and $Department o f  Experimental and Chemical. Endocrinology; St. Radboud University Hospital, Nijmegen* The Netherlands
Summary: in this; study we examined the effects of long-term 
treatment o f  19 patients with primary hypertension with the ß r  
adrenoceptor antagonist atenolol on norepinephrine and epi­
nephrine kinetics, at rest and during sympathoadrenal stimula­
tion by lower body negative pressure. Norepinephrine and 
epinephrine kinetics were measured by using the radioisotope- 
di luti on technique by steady-state infusion of tritiated norepi­
nephrine and epinephrine. The patients were studied before and 
at the end of  3 months o f  treatment with atenolol (50 or 100 mg 
daily). A control group o f  four normotensive subjects was stud­
ied before and after 3 months without any drug treatment. In this 
group, only arterial blood samples were collected without infu­
sion of the tritiated catecholamines. Atenolol decreased blood 
pressure and heart rate, but forearm vascular resistance was not 
affected by atenolol. During atenolol, baseline arterial plasma 
epinephrine decreased from 0.23 ± Ö.02 to Ü.17 ± O.Oì nM  (p <
0,05), and this was accompanied by a decrease in total body ep­
inephrine spillover from 0,50 ± 0.05 to 0.35 ± 0.04 nmol/min (p 
< 0.05), In the control group, arterial plasma epinephrine had not 
decreased after 3 months. In addition, the increment of arterial 
plasma epinephrine during lower body negative pressure a t -40 
mm Hg was attenuated during atenolol. Atenolol had no effect 
on total body and forearm norepinephrine spillover rates, either 
at rest or during lower body negative pressure. Clearance ivtes 
of epinephrine and norepinephrine were not significantly ef­
fected by atenolol. These results suggest that treatment of pa­
tients with primary hypertension with the ß j-adrenoceptor 
blocker atenolol inhibits the adrenomedullary secretion of epi­
nephrine, but it does not affect the biochemical indices of sym- 
pathoneural activity, It remains speculative whether this selec­
tive effect of atenolol on epinephrine secretion contributes to its 
hypotensive action and to its cardioprotective effects in the long 
term. KeyWords: ß (-Adrenergic— Sympathoadrenal activity— 
Hypertension— Catecholamines.
For a long time, ßpadrenoceptor blocking agents have 
been widely used as effective antihypertensive drugs. 
The mechanism through which they reduce blood pres­
sure is still incompletely understood but is presumed to 
be dependent on a competitive antagonism with endoge­
nous catecholamines at the ß-adrenoceptor sites. These 
ß-adrenoceptors are found pre- and postsynaptically in 
many tissues, like the heart, the brain, the adrenal 
medulla, and the resistance arteries. Several mechanisms 
have been suggested to be implicated in blood pressure 
reduction during ßj -blockade: resetting of the baroreflex, 
central nervous system mechanisms, decreased periph­
eral sympathetic discharge resulting from presynaptic ß- 
receptor inhibition, and reduction of cardiac output (1,2). 
Long-term treatment of patients with hypertension with 
ßj-blockers might have an effect on sympathetic nervous 
system activity, but plasma norepinephrine (NE) levels 
are not suited for a reliable assessment of sympathetic
nervous system activity. Plasma NE levels during long­
term treatment have been reported to be increased, un­
changed, or decreased (I). Plasma catecholamine levels 
are determined both by their spillover into the circulation 
and by their clearance from the circulation. The clear** 
ance, depending on cardiac output, might be affected by 
ß j-adrenoceptor blocking agents. To assess the effects of 
ßj-blockade on catecholamine spillover and clearance 
rates, the isotope-dilution method can be used (3). Previ­
ous studies, reporting on NE kinetics during long-term ß- 
blockade, showed decreased or unchanged NE spillover 
rates or decreased NE clearance rates (4,5). Epinephrine 
(EPI) kinetics during ß -^blockade have never been ex­
amined in humans. In this study we investigated the ef­
fects of 3 months’ treatment of patients with primary 
hypertension with atenolol on clearance and on sympa- 
thoneural and adrenomedullary spillovers of NE and EPI. 
This was earned out both at rest and during sympathoad­
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renal stimulation by lower-body negative pressure 
(LBNP).
SUBJECTS AND METHODS
Subjects
Nineteen patients with primary hypertension (12 men and 
seven women; mean ± SD age, 40.9 ±5.2 years) participated in 
the study. All participants had a normal physical examination 
before entry in the study. Secondary hypertension was excluded 
according to standard clinical criteria, and all subjects had nor­
mal renal function. The mean ± SD Quetelet index was 25.2 ± 
2.2 kg/m2. Thirteen of these 19 participants used antihyperten­
sive medication, which was discontinued >4 weeks before the 
study. After stopping the antihypertensive medication, blood 
pressure was measured 3 times at 2-week intervals, The mean ± 
SD basal systolic (SBP)/diastolic blood pressure (DBP) before 
treatment with atenolol was 156 ± 16/100 ± 8 mm Hg, and the 
heart rate (HR) was 70 ± II beats/min. Four normotensive sub­
jects (mean ± SD basal SBP/DBP, 125 ± 6/82 ± 5 mm Hg) 
served as a control group (mean ± SD age, 45.9 ± 2.1 years). All 
subjects gave their written informed consent. The study proto­
col was approved by the Hospital Ethics Committee.
Study protocol
All patients with hypertension were studied twice: before 
and after treatment with atenolol for 3 months. Each patient 
started with atenolol at 50 mg/day, and blood pressure was 
recorded every 3 weeks. The dose was increased to 100 mg/day 
after 6 weeks unless the HR had decreased by > 25% or to < 45 
beats/min. After 3 months, eight subjects were taking atenolol, 
50 mg/day, and 11 subjects were taking 100 mg/day. The con­
trol group of four normotensive subjects was also studied twice 
with an interval of 3 months. This group was enclosed to con­
trol for a time effect, so they did not receive atenolol. However, 
in this group we studied only the reproducibility of the arterial 
plasma catecholamine levels, and we did not use the tracer in­
fusions in this group.
On each study day, the subjects were allowed a light break­
fast. All participants were required to abstain from alcohol, 
nicotine, and eafieinated foods and beverages for > 24 h before 
each study day. All studies were carried out in the morning in a 
temperature-controlled room. During the study the subjects re­
mained supine in a LBNP box that was used to stimulate sym- 
pathoadrenoinedullary activity. After instrumentation, radio­
tracer infusions (see the following) were started, and the 
subjects rested for 30 min. During the last 3 min, baseline 
recordings of blood pressure, HR, and forearm blood flow were 
obtained. Then arterial and venous blood samples were drawn 
simultaneously to determine plasma concentrations of endoge­
nous and tritiated catecholamines. Thereafter, LBNP was ap­
plied at -15 mm Hg for 15 min. Blood pressure, HR, and fore­
arm blood-flow recordings and blood samples were collected in 
sequence beginning after 12 min of LBNP. A rest period of 30 
min ensued, and then another 15 min of LBNP at -40 mm Hg 
was applied, and blood pressure, MR, and forearm blood-flow 
recordings and blood samples were obtained as before.
Procedures
A brachial artery was cannulated to monitor blood pressure 
and HR (Hewlett Packard GmbH, Böblingen, Germany) and to 
draw arterial blood samples. An intravenous catheter was in­
serted into a deep brachial vein in the ip si lateral arm to collect 
venous blood samples. A forearm venous catheter in the con­
tralateral arm was used for simultaneous infusion of [3H]NE 
and [3H]EPI. Forearm blood flow was recorded by venous oc­
clusion strain-gauge plethysmography with air-filled cuffs (6). 
During the measurement of forearm blood flow and the sam­
pling of the blood samples, the hand circulation was excluded 
by inflation of a wrist cuff to 100 mm Hg above systolic blood 
pressure (7).
Radiotracer infusion
[3H]NE (levo-[ring-2,5,6-3H]NE and [3H]EPI (levo-|7V- 
methyl-3H]EPI, with high specific activity, were infused intra- 
venously to assess catecholamine kinetics. Tritiated cate­
cholamines were obtained from Du Pont New England Nuclear, 
Hertogenbosch, the Netherlands), sterilized by using a microp­
ore filter (0.22 pm), and diluted in NaCl 0.9%, containing 
acetic (0.2 M) and ascorbic (I mg/ml) acid. The vials were 
stored until use at -80°C for a maximum of 3 months. Steril­
ization, dilution, and storage took place under nitrogen, Just be­
fore the study, an aliquot of each radiotracer was diluted in nor­
mal saline.
After a bolus injection of each radiotracer at 15 pCi/m2, both 
tracers were infused for 90 min at a continuous rate of 0.35 
|iCi/m2/min. The weight of the two syringes containing the ra­
diotracers was measured before and after the infusion to verify 
the infusion rate. Samples of the infusate were taken at the end 
of the infusion and stored at -80°C until assayed.
Analytic methods
The blood samples were collected in prechilled tubes con­
taining 0.25 M  EGTA and 0.2 M glutathione in distilled water 
(pH, 7.4). The blood samples were placed on melting ice. 
Plasma was separated by refrigerated centrifugation and frozen 
until assayed, which occurred within 2 months after collection. 
The samples were analyzed for concentrations of both unla- 
beled and tritium-labeled NE and EPI by using high-perfor­
mance liquid chromatography (HPLC) with fluorimetrie detec­
tion after selective precol umn derivatization of the 
catecholamines with the fluorescent agent 1,2-diphenyIethyl- 
enediamine (8). By using a Gilson fraction collector (model 
201-202), connected to an automatic sample injector (Wisp 
710B), we collected [3H]NE and [3H]EPI into scintillation 
vials, starting at the beginning of the peaks of NE and EPI in the 
standard mixture.
Data analysis
Forearm vascular resistance (FVR) was calculated by divid­
ing mean arterial blood pressure (MAP) by forearm blood flow 
(FBF) and was expressed in arbitrary units (AU). The average 
of the hemodynamic data during 3 min was calculated.
The clearance rate of NE (L/min) from arterial plasma was 
calculated by dividing the infusion rate of [3H]NE (dpm/min) 
by the steady-state arterial plasma concentrations of [3H]NE 
(dpm/L). Tota! body NE spillover rate (nmol/min), the esti­
mated rate of appearance of endogenous NE in arterial plasma, 
was calculated by multiplying the steady-state arterial plasma 
NE concentration (nM) by the clearance (L/min). Analogously, 
NE spillover in the forearm was estimated as:
Forearm NE spillover (pmol/min/100 ml) =
FPF x NEa x  f  + [FPFx (NEa -  NEV)] (1)
where FPF is forearm plasma flow (mi/min/10Q ml), NE;l is ar­
terial plasma NE (nAf), NEV is venous plasma NE (nM), and f 
is the fractional extraction [(3HNEa — 3HNEV)/3HNE;,]. The
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forearm plasma flow was calculated from the forearm blood 
flow and hematocrit. The clearance of NE from the forearm 
(ml/min/100 ml) was calculated by multiplying the forearm 
plasma flow by the fractional extraction. The clearance of EPI 
from arterial plasma and the estimated rate of appearance of en­
dogenous EPI into arterial plasma were calculated according to
similar formulas.
Results are expressed as mean ± SEM unless indicated oth­
erwise. To test the effects of atenolol on baseline plasma kinetic 
variables, the Wilcoxon signed-rank test was performed. This 
test also was used to test for the effects of LBNP and to com­
pare the responses to LBNP before and during atenolol. A p 
value of < 0.05 (two-tailed) was considered to be significant.
RESULTS
Hemodynamic data
After treatment with atenolol, SBP and DBP decreased 
significantly from 166 ± 4/89 ± 2 to .146 ± 4/75 ± 3  mm 
Hg (p < 0.05). HR decreased from 60 ± 3 to 49 ± 2 
beats/min (p < 0.05). FBF and FVR were not signifi­
cantly affected by atenolol (1.91 ± 0.25 and 1.72 ± 0.22 
ml/min/100 ml and 81.4 ± 8.7 and 80.9 ± 9.4 AU, re­
spectively).
LBNP at -1 5  mm Hg had no effects on SBP, DBP, and 
HR both before and after atenolol. The increase in FVR 
at LBNP o f - 15 mm Hg was not affected by atenolol. The 
BP responses to LBNP at -4 0  mm Hg were not altered, 
whereas the increase in HR was impaired (+8 ± 1 
beats/min before and +5 ± 1 beats/min after atenolol; p < 
0.05). The increase in FVR to LBNP at -4 0  mm Hg was 
similar before and after atenolol.
Plasma epinephrine kinetics
After treatment with atenolol, the subjects had an 
-35%  lower basal arterial plasma EPI than before treat­
ment (Table 1). This decrease in arterial plasma EPI was 
accompanied by a significant decrease in total body EPI 
spillover (Fig. 1), whereas total body clearance and fore­
arm clearance of EPI were not altered by atenolol (Table 
1). In the control group, we could not demonstrate a de-
TABLE 1. Plasma levels and kinetics of epinephrine and 
norepinephrine before and after treatment with atenolol
Before
atenolol
After
atenolol
Epinephrine
Arterial plasma level (iiM)
Total body spillover (nmol/min)
Total body clearance (L/min) 
Forearm clearance (ml/100 ml/min) 
Norepinephrine
Arterial plasma level (nM)
Total body spillover (nmol/min)
Total body clearance (L/min) 
Forearm spillover (pmol/100 ml/min) 
Forearm clearance (ml/100 ml/min)
0.23 ± 0.02" 
0.50 ± 0.05“ 
2.20 ±0.11 
0.83 ± 0 .0 9
0.98 ± 0 .1 0  
1.82 + 0.16 
1.95 ± 0 ,13  
0.87 ± 0.09 
0.78 ± 0.08
0.17 ±0.01  
0.35 ± 0.04 
2.10 ± 0.12 
0.69 ± 0.07
0.92 ± 0.09 
1.75 ± 0.26 
1.85 ±0.11  
0.82 ± 0 .1 0  
0.63 ± 0.06
Mean ± SEM are given.
rtp < 0.05.
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FIG. 1. Individual values of total body epinephrine (EPI) spillover 
and forearm norepinephrine (NE) spillover before (B) and after 
(A) 3 months’ treatment with atenolol, ‘p < 0.05.
crease in basal arterial plasma EPI when the subjects 
were restudied after 3 months: 0.29 ± 0.07 and 0.28 ± 
0.06 nM, respectively,
The responses of total body EPI spillover and clear­
ance and o f  forearm EPI clearance to LBNP at -15 mm 
Hg EPI were not affected by atenolol. However, atenolol 
did attenuate the increase in total body EPI spillover to 
LBNP at -4 0  mm Hg (+0.77 ± 0.26 nmol/min before and 
0.21 ± 0.04 nmol/min after atenolol; p < 0.05; Fig, 2), 
whereas the responses of total body and forearm clear­
ance rates were not affected by atenolol. The attenuated 
response in total body EPI spillover to LBNP at -40  mm 
Hg after atenolol was reflected by an attenuated increase 
in arterial plasma EPI concentration to LBNP at -40  mm 
Hg after atenolol, although the difference was not signif­
icant (+0.52 ± 0.14 nM before and +0.23 ± 0.03 nM after
atenolol; p = 0.11).
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FIG. 2. The responses of total body spillover of epinephrine 
(TBSE, nmol/min) and norepinephrine (TBSNE, nmol/min), fore­
arm spillover of norepinephrine (FASNE, pmol/100 ml/min), total 
body clearance of epinephrine (TBCLE, L/min), and norepineph­
rine (TBCNE, L/min) and forearm clearance of norepinephrine 
(FACNE, ml/100 ml forearm volume/min) to lower-body negative 
pressure at -40 mm Hg before (black bars) and after (open bars) 
long-term treatment with atenolol. Mean ± SEM are given.
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Plasma norepinephrine kinetics
Baseline arterial plasma NE, total body NE spillover, 
and total body NE clearance were not affected by treat­
ment with atenolol. Forearm NE spillover (Fig. 1) and 
forearm NE clearance also were not changed by atenolol 
(Table 1). The responses of forearm NE spillover and to­
tal body NE spillover, as well as forearm clearance and 
total body clearance of NE to LBNP at -1 5  mm Hg and 
at -40 mm Hg, were not altered by atenolol.
DISCUSSION
The principal finding of our study is that long-term 
treatment with the ß j -adrenoceptor-blocking agent 
atenolol decreases total body EPI spillover, whereas it 
does not affect total body NE spillover. The plasma clear­
ance rates of both NE and EPI are not decreased by 
atenolol. Because the total body EPI spillover reflects the 
release of EPI from the adrenal medulla, these data imply 
that chronic ß r adrenergic blockade attenuates adreno­
medullary EPI release but does not affect sympa- 
thoneural NE spillover. In addition, EPI and NE spillover 
and clearance during sympathoadrenal stimulation by 
LBNP at -15  mm Hg are not affected by atenolol, 
whereas the adrenomedullary secretion of EPI during 
LBNP at -4 0  mm Hg is attenuated. Long-term adminis­
tration of atenolol does reduce baseline as well as stimu­
lated release of EPI from the adrenal medulla in patients 
with primary hypertension.
Several mechanisms should be discussed to explain 
the differentiated response of the sympathetic nervous 
system during long-term treatment with atenolol, leading 
to diminished EPI release from the adrenal medulla with 
a concomitant unchanged NE spillover. First, diminished 
adrenomedullary EPI release might be a direct effect of 
blockade of facilitatory ß j-adrenoceptors on the 
adrenomedullary chromaffin cell membranes, as was 
shown in rat adrenal medulla cells in vitro (9). In con­
trast, the presynaptic ß-adrenoceptors at the sympathetic 
nerve endings appear to be of the ß2-subtype, and there­
fore the NE spillover is not expected to decrease during 
atenolol administration (2). Second, a decreased circulat­
ing EPI concentration might result from a decreased 
sympathetic impulse nerve traffic to the adrenal medulla. 
This, however, would not be consistent with the un­
changed NE spillover, unless atenolol would affect ex­
clusively the sympathetic outflow to the adrenal medulla. 
Finally, the decreased arterial plasma EPI levels and the 
decreased EPI release from the adrenal medulla could be 
a time effect or could be just the expression of an attenu­
ated defense reaction to the stress of the experimental 
procedure. However, in a small control group, plasma 
EPI levels were not reduced at a second arterial cannula- 
tion after 3 months. The ideal study setup with a ran­
domized crossover design with placebo and atenolol 
would require, however, withholding antihypertensive 
therapy to patients with hypertension for at least another 
3 months. Although this is not a randomized crossover 
study, the unchanged plasma EPI levels after 3 months in
the control group argue against an aspecific effect, al­
though this can not be excluded definitely on the basis of 
this study.
Data on catecholamine spillover and clearance rates 
during long-term ß L-adrenergic blockade in human hy­
pertension are not available from previous studies. EPI 
kinetics during ß-blockade in humans has never been 
studied. NE kinetics were studied after short-term ad­
ministration of ß r selective (5) and nonselective ß-block- 
ers (4) or long-term administration of nonselective ß- 
blockers (10). These data are hard to compare with our 
data on long-term ß r blockade, because short-term ad­
ministration of ß-blocking agents or the use of nonselec­
tive ß-blockade shows important differences with regard 
to sympathetic nervous activity, organ blood flow, or ß- 
receptor occupation, thus influencing catecholamine ki­
netics.
Short-term administration o f  a selective or nonselec­
tive ß-blocker causes a reduction of cardiac output and a 
baroreflex-mediated increase in total peripheral resis­
tance, whereas peripheral resistance generally returns to 
the pretreatment level during chronic ß-blockade (1). The 
increased intraneuronally measured muscle sympathetic 
activity after a bolus injection with a ß -b lo ck e r  is re­
stored during long-term ß r blockade (11,12). Moreover, 
baroreflex sensitivity is increased after long-term ß- 
blocker treatment but not after short-term administration 
(13,14). In addition to baroreceptor-mediated effects on 
sympathetic outflow, catecholamine kinetics are influ­
enced at the synaptic level by local blood flow, because 
catecholamine clearance is blood-flow dependent (5). A 
nonselective ß-blocker has different sites of actions from 
those of a ß | -selective blocker, which may affect cate­
cholamine kinetics as weil. NE release from the sympa­
thetic nerve terminals is modulated by presynaptic ß2- 
adrenoceptors, which can be blocked by a nonselective 
blocker but probably not by ß r selective blockers. NE 
clearance is more ß2-adrenoceptor dependent than ß t- 
adrenoceptor dependent, because in rats, NE clearance is 
decreased by propranolol but not by atenolol (15). In a 
study with intraarterial ß-blocker infusions, thus prevent­
ing systemic hemodynamic effects, both metoprolol and 
propranolol decreased NE spillover (5). There are, how­
ever, no inhibitory ß ¡-adrenoceptors on sympathetic 
nerve terminals. Alternatively it remains possible that the 
high local dose of metoprolol that was used was not ß r  
selective.
The EPI-spillover response to LBNP at -4 0  mm Hg 
was attenuated, although the NE-spillover response was 
not changed. The neurohumoral responses to sympathoa­
drenal stimulation during ß j -adrenoceptor blockade have 
never been assessed* Our data on NE kinetics confirm and 
extend earlier observations using microneurography that 
demonstrated that responses of sympathetic nerve traffic 
to graded LBNP were not attenuated by propranolol (16).
In conclusion, the results of this study suggest that 
treatment of patients with primary hypertension with the 
ß r adrenoceptor blocker atenolol inhibits the basal and 
stimulated adrenomedullary secretion of EPI, whereas it
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does not affect the biochemical indices of sympathoneural 
activity. It remains speculative whether this selective ef­
fect of atenolol on epinephrine secretion contributes to its 
hypotensive action and to its cardioprotective effects in 
the long term.
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